All In Biotech

NDA 202211 · Abbvie

Oxytrol For Women

Oxybutynin · Transdermal · Cholinergic Muscarinic Antagonist

Last checked: Nov 20, 2026Latest source record: Mar 3, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jan 25, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

103

25 Phase 3, 9 recruiting

FAERS reports

28,263

13,571 serious, 1,688 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 15, 2024.

Use treats overactive bladder in women you may be suffering from overactive bladder if you have had 2 or more of the following symptoms for at least 3 months: ○ urinary frequency (the need to urinate more often than usual; typically more than 8 times in 24 hours) ○ urinary urgency (a strong need to urinate right away) ○ urge incontinence (leaking or wetting yourself if you cannot control the urge to urinate) non-drug therapies may also help you (see the consumer information leaflet inside the package)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • OXYTROL FOR WOMEN · OXYBUTYNIN 3.9MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxybutynin" as an intervention, any sponsor and status, largest first.

All 103 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,815
  • fatigue1,549
  • fall1,463
  • off label use1,258
  • nausea1,218
  • dizziness1,122
  • diarrhoea1,110
  • pain1,071
  • urinary tract infection1,045
  • headache986
  • pruritus950
  • asthenia900

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004178
2005196
2006150
200743
200855
200990
2010345
2011572
2012725
20131,492
20145,252
20152,300
20161,799
20171,880
20182,030
20192,054
20201,776
20211,500
20221,477
20231,350
20241,023
20251,144
2026831

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 392 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.